NASDAQ:BYSI

BeyondSpring Stock Forecast, Price & News

$11.43

+0.06 (+0.53 %)

(As of 06/11/2021 12:00 AM ET)

Add

Compare

Today's Range

$11.17

▼

$11.59

50-Day Range

$9.37

▼

$12.12

52-Week Range

$9.24

▼

$21.50

Volume114,678 shs

Average Volume186,729 shs

Market Capitalization$447.37 million

P/E RatioN/A

Dividend YieldN/A

Beta0.54

30 days | 90 days | 365 days | Advanced Chart

Receive BYSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BeyondSpring and its competitors with MarketBeat's FREE daily newsletter.

About BeyondSpring

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and developing Plinabulin, which is in Phase III clinical trial for the treatment of later-stage non-small cell lung cancer (NSCLC). It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.

BeyondSpring (BYSI) to Release Earnings on Wednesday
June 12, 2021 | americanbankingnews.com

BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021 - GlobeNewswire
June 11, 2021 | globenewswire.com

BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021
June 11, 2021 | finance.yahoo.com

BeyondSpring Announces Final Positive Data from the - GlobeNewswire
June 10, 2021 | globenewswire.com

BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting
June 10, 2021 | finance.yahoo.com

William Blair Comments on BeyondSpring Inc.'s Q1 2021 Earnings (NASDAQ:BYSI)
June 9, 2021 | americanbankingnews.com

BeyondSpring Announces a Late-Breaking Poster Presentation - GlobeNewswire
June 8, 2021 | globenewswire.com

BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced Neutropenia (CIN) at the FOCIS Annual Meeting
June 8, 2021 | finance.yahoo.com

BeyondSpring (BYSI) to Present Three Abstracts from PROTECTIVE-2 Phase 3 Trials of Plinabulin at ASCO - StreetInsider.com
June 7, 2021 | streetinsider.com

BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin - GlobeNewswire
June 7, 2021 | globenewswire.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BYSI
Previous Symbol
CUSIPN/A
CIK1677940
Webwww.beyondspringpharma.com
Phone1-646-305-6387
Employees91
Year FoundedN/A

Sales & Book Value

Annual Sales$180,000.00
Price / Sales2,485.39
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.21 per share
Price / Book5.17

Profitability

EPS (Most Recent Fiscal Year)($2.03)
Net Income$-60,970,000.00
Net MarginsN/A
Return on Equity-153.24%
Return on Assets-103.06%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares39,140,000
Market Cap$447.37 million
Next Earnings Date6/16/2021 (Confirmed)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.31 out of 5 stars

Medical Sector

856th out of 2,100 stocks

Pharmaceutical Preparations Industry

414th out of 830 stocks

3.3 Analyst's Opinion

Consensus Rating
BeyondSpring has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $32.67, BeyondSpring has a forecasted upside of 185.8% from its current price of $11.43.
Amount of Analyst Coverage
BeyondSpring has only been the subject of 1 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
BeyondSpring has received 175 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
BeyondSpring has received 163 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
BeyondSpring has received 51.78% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about BeyondSpring and other stocks. Vote “Outperform” if you believe BYSI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BYSI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
BeyondSpring does not currently pay a dividend.
Dividend Growth
BeyondSpring does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BeyondSpring insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 18.02% of the stock of BeyondSpring is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for BeyondSpring are expected to grow in the coming year, from ($2.40) to ($1.70) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BeyondSpring is -5.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BeyondSpring is -5.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BeyondSpring has a P/B Ratio of 5.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

BeyondSpring (NASDAQ:BYSI) Frequently Asked Questions

Is BeyondSpring a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeyondSpring in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BeyondSpring stock.
View analyst ratings for BeyondSpring or view top-rated stocks.

What stocks does MarketBeat like better than BeyondSpring?

Wall Street analysts have given BeyondSpring a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BeyondSpring wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BeyondSpring's next earnings date?

BeyondSpring is scheduled to release its next quarterly earnings announcement on Wednesday, June 16th 2021.
View our earnings forecast for BeyondSpring.

How can I listen to BeyondSpring's earnings call?

BeyondSpring will be holding an earnings conference call on Wednesday, June 16th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were BeyondSpring's earnings last quarter?

BeyondSpring Inc. (NASDAQ:BYSI) issued its quarterly earnings data on Thursday, April, 29th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by $0.07.
View BeyondSpring's earnings history.

How has BeyondSpring's stock been impacted by COVID-19?

BeyondSpring's stock was trading at $11.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BYSI shares have increased by 0.7% and is now trading at $11.43.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for BYSI?

3 brokers have issued 12-month price objectives for BeyondSpring's stock. Their forecasts range from $25.00 to $43.00. On average, they anticipate BeyondSpring's stock price to reach $32.67 in the next twelve months. This suggests a possible upside of 185.8% from the stock's current price.
View analysts' price targets for BeyondSpring or view top-rated stocks among Wall Street analysts.

Who are BeyondSpring's key executives?

BeyondSpring's management team includes the following people:

Dr. Lan Huang, Co-Founder, Chairman & CEO (Age 50)
Ms. Elizabeth Adkins Czerepak, Chief Financial Officer (Age 65)
Mr. Richard J. Daly M.B.A., Chief Operating Officer (Age 60)
Dr. G. Kenneth Lloyd, Chief Scientific Officer (Age 77)
Stephen Kilmer, Head of Investor Relations
Mr. Gregg Russo, Sr. VP of HR
Dr. Ramon W. Mohanlal, Exec. VP of R&D, Chief Medical Officer and Director (Age 63)
Dr. Gordon L. Schooley, Chief Regulatory Officer (Age 74)
Mr. Paul Friel, Chief Commercial Officer

Who are some of BeyondSpring's key competitors?

Some companies that are related to BeyondSpring include Cerevel Therapeutics (CERE), Madrigal Pharmaceuticals (MDGL), Arcus Biosciences (RCUS), Zymeworks (ZYME), Applied Molecular Transport (AMTI), Supernus Pharmaceuticals (SUPN), uniQure (QURE), PureTech Health (PRTC), Y-mAbs Therapeutics (YMAB), Aurinia Pharmaceuticals (AUPH), Indivior (INVVY), Constellation Pharmaceuticals (CNST), COMPASS Pathways (CMPS), Heron Therapeutics (HRTX) and Generation Bio (GBIO).
View all of BYSI's competitors.

What other stocks do shareholders of BeyondSpring own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), Pfizer (PFE), Atara Biotherapeutics (ATRA), CorMedix (CRMD) and Dynavax Technologies (DVAX).

When did BeyondSpring IPO?

(BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) acted as the underwriter for the IPO.

What is BeyondSpring's stock symbol?

BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI."

Who are BeyondSpring's major shareholders?

BeyondSpring's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (6.55%), BlackRock Inc. (3.11%), Blair William & Co. IL (0.60%), Northern Trust Corp (0.51%), Nuveen Asset Management LLC (0.44%) and Geode Capital Management LLC (0.44%).

Which major investors are selling BeyondSpring stock?

BYSI stock was sold by a variety of institutional investors in the last quarter, including Endurance Wealth Management Inc., Millennium Management LLC, Russell Investments Group Ltd., and UBS Group AG.

Which major investors are buying BeyondSpring stock?

BYSI stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., BlackRock Inc., Blair William & Co. IL, Diametric Capital LP, Geode Capital Management LLC, Nuveen Asset Management LLC, Morgan Stanley, and Goldman Sachs Group Inc..

How do I buy shares of BeyondSpring?

Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeyondSpring's stock price today?

One share of BYSI stock can currently be purchased for approximately $11.43.

How much money does BeyondSpring make?

BeyondSpring has a market capitalization of $447.37 million and generates $180,000.00 in revenue each year. The company earns $-60,970,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.

How many employees does BeyondSpring have?

BeyondSpring employs 91 workers across the globe.

What is BeyondSpring's official website?

The official website for BeyondSpring is www.beyondspringpharma.com.

Where are BeyondSpring's headquarters?

BeyondSpring is headquartered at 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005.

How can I contact BeyondSpring?

BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 1-646-305-6387 or via email at [email protected]

This page was last updated on 6/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here